MAP2K7 and Papillary Craniopharyngioma: In addition to three case reports, the efficacy of combining BRAF and MEK inhibitors in a neoadjuvant regimen was confirmed in a phase-2 clinical trial (NCT03224767) including 16 patients with newly diagnosed papillary craniopharyngiomas, treated in 28-day cycles (Table 9) [18] and in a recent cohort of 6 patients [20].